Publications by authors named "Rivkah Hornbacher"
Oxytocin Reduces Noradrenergic-Induced Opioid-Like Withdrawal Symptoms in Individuals on Opioid Agonist Therapy.
Biol Psychiatry Glob Open Sci
January 2025
Background: Intranasal administration of the neuropeptide oxytocin has been explored as a potential therapeutic agent for substance use disorder including opioid use disorder (OUD).
Methods: This phase 1, crossover, randomized, double-blind, placebo-controlled trial tested the safety, tolerability, and efficacy of intranasal oxytocin (80 IU) twice a day for 7 days in participants ( = 20) with OUD who were taking an opioid agonist therapy. In the laboratory, participants underwent opioid cue exposure paired with noradrenergic activation produced by yohimbine (32.
Probenecid as a pharmacotherapy for alcohol use disorder: A randomized placebo-controlled alcohol interaction trial.
Alcohol Clin Exp Res (Hoboken)
December 2024
Article Synopsis
- - This study provides early evidence that pannexin 1 channels could be a new target for creating treatments for alcohol use disorder (AUD), highlighting probenecid’s potential due to its long safety history and ability to reduce excessive alcohol intake in animal models.
- - A randomized trial involving 35 participants explored the effects of a 2g dose of probenecid taken with alcohol, measuring various outcomes like alcohol craving and cognitive function, finding no significant impact on alcohol absorption or overall cognitive ability.
- - Results indicated that probenecid notably reduced alcohol cravings during the early phase of intoxication, supporting its potential as a treatment for AUD and emphasizing the need for further research on pannexin 1 channels for new drug development